The EPS beat is modest and on a small base typical of pre-revenue biotechs. Monitor upcoming clinical trial readouts (RESOLVE Phase 1b/2 for EP-104GI) and any financing events, as the company will require additional capital to advance its pipeline.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals reported Q1 2026 EPS of -$0.23, beating consensus estimates of -$0.26 by 9.8%. The filing covers the results of the Annual General Meeting, including the election of directors and re-appointment of auditor, with no material financial or operational updates beyond the EPS beat.
Key Financial Metrics
Key Facts
- EPS of -$0.23 beat consensus of -$0.26 by 9.8%
- Revenue was $0 (pre-revenue clinical-stage biotech)
- All seven director nominees were elected with overwhelming shareholder support
- KPMG LLP re-appointed as auditor
- No guidance, pipeline updates, or financial projections provided
Financial Impact
EPS beat of 9.8% on a small absolute base (-$0.23 vs -$0.26); no revenue or cash flow impact
Risk Factors
- Pre-revenue stage with no approved products; requires future financing
- Clinical trial risks for EP-104GI (EoE) and EP-104IAR (knee OA)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314889 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 27d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 27d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers